Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis modelBRAVE, Sandra R; EBERLEIN, Cath; SHIBUYA, Masabumi et al.Angiogenesis (London). 2010, Vol 13, Num 4, pp 337-347, issn 0969-6970, 11 p.Article

AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerBRAVE, Sandra R; ODEDRA, Rajesh; WAINWRIGHT, Anna et al.International journal of oncology. 2011, Vol 39, Num 1, pp 271-278, issn 1019-6439, 8 p.Article